In a report released yesterday, Peter Lawson from Barclays assigned a Hold rating to Blueprint Medicines (BPMC – Research Report), with a price target of $70.00. The company’s shares closed yesterday at $77.54.
According to TipRanks, Lawson is a 4-star analyst with an average return of 8.5% and a 45.53% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Exelixis, and ImmunoGen.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $93.08 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $94.00 and a one-year low of $37.82. Currently, Blueprint Medicines has an average volume of 788.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blueprint Medicines (BPMC) Company Description:
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Read More on BPMC:
- BPMC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Blueprint Medicines price target raised to $90 from $85 at Oppenheimer
- Blueprint Medicines price target raised to $78 from $58 at Piper Sandler
- Blueprint Medicines says AYVAKIT has potential to be multibillion-dollar therapy
- Blueprint Medicines price target raised to $114 from $89 at Goldman Sachs
